New issue of shares in medivir and completion of mimetrix acquisition
NEW ISSUE OF SHARES IN MEDIVIR AND COMPLETION OF MIMETRIX ACQUISITION th The Board of Directors of Medivir AB (publ) decided on April 9 2000 to issue 1,405,000 new shares of series B. The decision was made under the th mandate given by the shareholders' Annual General Meeting on March 29 2000. The proceeds from the new issue of shares will be used to finance Medivir's future expansion and has also contributed in increasing the company's institutional ownership in Sweden and internationally. The recent announcement of the acquisition of Mimetrix, Cambridge, from Peptide Therapeutics Group plc, was subject to the successful completion of this new issue of shares. Thus, the acquisition of Mimetrix, payable through a non-cash issue of 95,000 Medivir class B shares, will now be completed. In total, this means that the number of series B shares will increase by 1,500,000. Net proceeds to Medivir amount to approximately SEK 296 million. Jonas Frick, CEO of Medivir: "We are very pleased with the interest and reception we have received from the investors that we have met during the roadshow. The new issue of shares is an important step for Medivir in its continued expansion. Together with Mimetrix we now have an enhanced capacity and the ability to increase the pace of development of candidate drugs, thus creating more value to our shareholders." The new issue of shares has been directed to a number of Swedish and international institutional investors. The issue price has been determined to SEK 220 per share through a book- building procedure. The new issue was substantially oversubscribed. Fleming Aros has acted as financial advisor to Medivir in the new issue of shares and in connection with the acquisition of Mimetrix. th Huddinge April 10 2000 Medivir AB (publ) For further information please contact: Jonas Frick, CEO: Tel +46 8-608 31 17, +46 70-648 67 61or Per Baumann, CFO: Tel +46-8-608 31 18, +46-70-375 50 30 Information about Medivir on internet : www.medivir.se Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. Medivir has been listed on the Stockholm Stock Exchange since November 1996. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/2000/04/10/20000410BIT00580/bit0001.doc http://www.bit.se/bitonline/2000/04/10/20000410BIT00580/bit0002.pdf